A detailed history of Castleark Management LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Castleark Management LLC holds 51,880 shares of ITCI stock, worth $4.31 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
51,880
Previous 53,780 3.53%
Holding current value
$4.31 Million
Previous $3.68 Million 2.99%
% of portfolio
0.16%
Previous 0.15%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.99 - $80.84 $129,180 - $153,596
-1,900 Reduced 3.53%
51,880 $3.79 Million
Q2 2024

Aug 13, 2024

SELL
$64.76 - $79.84 $29,142 - $35,928
-450 Reduced 0.83%
53,780 $3.68 Million
Q1 2024

May 15, 2024

SELL
$64.37 - $75.65 $1.26 Million - $1.48 Million
-19,570 Reduced 26.52%
54,230 $3.75 Million
Q4 2023

Feb 14, 2024

SELL
$46.37 - $73.65 $4,637 - $7,365
-100 Reduced 0.14%
73,800 $5.29 Million
Q3 2023

Nov 15, 2023

SELL
$52.09 - $64.1 $176,585 - $217,298
-3,390 Reduced 4.39%
73,900 $3.85 Million
Q2 2023

Aug 15, 2023

BUY
$54.67 - $66.44 $2.9 Million - $3.53 Million
53,120 Added 219.78%
77,290 $4.89 Million
Q1 2023

May 15, 2023

SELL
$43.8 - $56.99 $1.63 Million - $2.12 Million
-37,200 Reduced 60.62%
24,170 $1.31 Million
Q4 2022

Feb 09, 2023

SELL
$44.07 - $54.45 $1.18 Million - $1.46 Million
-26,810 Reduced 30.4%
61,370 $3.25 Million
Q3 2022

Nov 15, 2022

SELL
$42.7 - $59.99 $85,400 - $119,980
-2,000 Reduced 2.22%
88,180 $4.1 Million
Q2 2022

Aug 16, 2022

BUY
$43.0 - $65.64 $2.15 Million - $3.28 Million
49,910 Added 123.94%
90,180 $5.15 Million
Q1 2022

May 16, 2022

BUY
$38.74 - $62.09 $1.56 Million - $2.5 Million
40,270 New
40,270 $2.46 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $7.85B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Castleark Management LLC Portfolio

Follow Castleark Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Castleark Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Castleark Management LLC with notifications on news.